340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
CHA's Response to The MAHA Commission's Make Our Children Healthy Again: Assessment
The Children's Hospital Association encourages HHS to support, engage with, and build upon children’s hospitals’ child health improvement initiatives taking place across the country.
Resources for IV Fluid Mitigation
CHA is sharing information from children’s hospitals and industry experts to help address IV fluid disruption in the wake of Hurricane Helene.
Children's Hospital Association's 2024 End of Year Letter to Congress
The letter highlights CHA's end of year priorities and asks Congress to take action to sustain children’s hospitals’ ability to provide care to our nation’s children.
CHA Submits Letter to HHS on Baxter Closure
The letter thanks HHS for their response to supply shortages caused by Hurricane Helene and urges continued support for pediatric needs during ongoing IV solution shortages.
High-Cost Therapies for Pediatrics
Pediatric HCTs are innovative and lifesaving or life-altering treatments for children with chronic, rare, and complex conditions.
Summary of Laboratory Developed Tests Final Rule
Children's Hospital Association sent a letter to Energy and Commerce leaders supporting pediatric-focused legislation included in a recent markup.
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
Addressing Pediatric Drug and Supply Shortages
Children’s hospitals depend on a reliable and safe drug and supply chain to provide life-saving treatments to their pediatric patients.
CHA Comments on Stimulant Medication Shortages
Children’s health groups are asking HHS and the DEA to convene stakeholders to identify actionable solutions about ongoing stimulant medication shortages.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.
